Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Neoplasms
Interventions: DRUG: VIP152 (BAY 1251152)|DRUG: VIP152 (BAY 1251152) 30 mg|DRUG: Keytruda|DRUG: VIP152 (BAY 1251152) 15 mg
Sponsor: Vincerx Pharma, Inc.